The effect of plasma protein binding on in vivo efficacy: misconceptions in drug discovery
- PMID: 21119731
- DOI: 10.1038/nrd3287
The effect of plasma protein binding on in vivo efficacy: misconceptions in drug discovery
Abstract
Data from in vitro plasma protein binding experiments that determine the fraction of protein-bound drug are frequently used in drug discovery to guide structure design and to prioritize compounds for in vivo studies. However, we consider that these practices are usually misleading, because in vivo efficacy is determined by the free (unbound) drug concentration surrounding the therapeutic target, not by the free drug fraction. These practices yield no enhancement of the in vivo free drug concentration. So, decisions based on free drug fraction could result in the wrong compounds being advanced through drug discovery programmes. This Perspective provides guidance on the application of plasma protein binding information in drug discovery.
Similar articles
-
Do we need to optimize plasma protein and tissue binding in drug discovery?Curr Top Med Chem. 2011;11(4):450-66. doi: 10.2174/156802611794480918. Curr Top Med Chem. 2011. PMID: 21320069 Review.
-
Plasma protein binding in drug discovery and development.Comb Chem High Throughput Screen. 2010 Feb;13(2):170-87. doi: 10.2174/138620710790596745. Comb Chem High Throughput Screen. 2010. PMID: 20053162 Review.
-
The impact of low temperature on fraction unbound for plasma and tissue.Biopharm Drug Dispos. 2018 Nov;39(9):437-442. doi: 10.1002/bdd.2160. Epub 2018 Nov 13. Biopharm Drug Dispos. 2018. PMID: 30362129
-
High performance affinity chromatography (HPAC) as a high-throughput screening tool in drug discovery to study drug-plasma protein interactions.J Pharm Biomed Anal. 2013 Feb 23;74:205-12. doi: 10.1016/j.jpba.2012.10.030. Epub 2012 Nov 5. J Pharm Biomed Anal. 2013. PMID: 23245252
-
A novel method using nuclear magnetic resonance for plasma protein binding assessment in drug discovery programs.J Pharm Biomed Anal. 2019 Apr 15;167:21-29. doi: 10.1016/j.jpba.2019.01.049. Epub 2019 Jan 31. J Pharm Biomed Anal. 2019. PMID: 30738240
Cited by
-
Pharmacologic activity and pharmacokinetics of metabolites of regorafenib in preclinical models.Cancer Med. 2016 Nov;5(11):3176-3185. doi: 10.1002/cam4.883. Epub 2016 Oct 13. Cancer Med. 2016. PMID: 27734608 Free PMC article.
-
Single-cell and subcellular pharmacokinetic imaging allows insight into drug action in vivo.Nat Commun. 2013;4:1504. doi: 10.1038/ncomms2506. Nat Commun. 2013. PMID: 23422672 Free PMC article.
-
A Kunitz-type inhibitor from tick salivary glands: A promising novel antitumor drug candidate.Front Mol Biosci. 2022 Aug 16;9:936107. doi: 10.3389/fmolb.2022.936107. eCollection 2022. Front Mol Biosci. 2022. PMID: 36052162 Free PMC article. Review.
-
Quantitative imaging of receptor-ligand engagement in intact live animals.J Control Release. 2018 Sep 28;286:451-459. doi: 10.1016/j.jconrel.2018.07.032. Epub 2018 Jul 20. J Control Release. 2018. PMID: 30036545 Free PMC article.
-
In vitro Evaluation of Isoniazid Derivatives as Potential Agents Against Drug-Resistant Tuberculosis.Front Pharmacol. 2022 May 4;13:868545. doi: 10.3389/fphar.2022.868545. eCollection 2022. Front Pharmacol. 2022. PMID: 35600870 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical